Vanguard Group Discloses Stake in Oxford Biomedica

The Vanguard Group, Inc. has disclosed its position in Oxford Biomedica plc under Form 8.3, a requirement of the UK's Takeover Code. The disclosure, dated February 23, 2026, reveals that Vanguard holds a 1.00% interest in the company, amounting to 1,209,428 ordinary shares.

The form also details recent transactions involving Oxford Biomedica's securities. Vanguard reported the sale of 2,090 ordinary shares at a price of 7.92 GBP per share. Notably, there are no other agreements, arrangements, or understandings concerning options or derivatives related to Oxford Biomedica, nor any supplemental positions disclosed.

This public disclosure highlights Vanguard's watchful positioning in the biotechnology firm amid market speculations. For further inquiries, contact Shawn Acker at the provided phone number.